Efficacy and safety of celivarone, with amiodarone as calibrator, in patients with an implantable cardioverter-defibrillator for prevention of implantable cardioverter-defibrillator interventions or death: the ALPHEE study.

@article{Kowey2011EfficacyAS,
  title={Efficacy and safety of celivarone, with amiodarone as calibrator, in patients with an implantable cardioverter-defibrillator for prevention of implantable cardioverter-defibrillator interventions or death: the ALPHEE study.},
  author={Peter R. Kowey and Harry J.G.M. Crijns and Etienne M. Aliot and Alessandro Capucci and Piotr Kulakowski and David Radzik and Denis Roy and Stuart J. Connolly and Stefan H. Hohnloser},
  journal={Circulation},
  year={2011},
  volume={124 24},
  pages={
          2649-60
        }
}
BACKGROUND Celivarone is a new antiarrhythmic agent developed for the treatment of ventricular arrhythmias. This study investigated the efficacy and safety of celivarone in preventing implantable cardioverter-defibrillator (ICD) interventions or death. METHODS AND RESULTS Celivarone (50, 100, or 300 mg/d) was assessed compared with placebo in this randomized, double-blind, placebo-controlled, parallel-group study. Amiodarone (200 mg/d after loading dose of 600 mg/d for 10 days) was used as a… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 23 CITATIONS

Ranolazine in High-Risk Patients With Implanted Cardioverter-Defibrillators: The RAID Trial.

  • Journal of the American College of Cardiology
  • 2018
VIEW 2 EXCERPTS
CITES BACKGROUND

Treatment of persistent ventricular tachycardia: Drugs or ablation?

  • Trends in cardiovascular medicine
  • 2017
VIEW 1 EXCERPT
CITES BACKGROUND

European Heart Rhythm Association/Heart Failure Association joint consensus document on arrhythmias in heart failure, endorsed by the Heart Rhythm Society and the Asia Pacific Heart Rhythm Society.

  • Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology
  • 2016

References

Publications referenced by this paper.
SHOWING 1-10 OF 13 REFERENCES

Role of antiarrhythmic drugs in patients with implantable cardioverter defibrillators

H Van Herendael, A Pinter, +3 authors P. Dorian
  • 2010

In vivo and in vitro characterization of the novel antiarrhythmic agent SSR149744C: electrophysiological, antiadrenergic, and anti-angiotensin II effects

P Gautier, E Guillemare, +5 authors D. Nisato
  • J Cardiovasc Pharmacol
  • 2004